Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Reumatismo ; 58(1): 59-61, 2006.
Article in Italian | MEDLINE | ID: mdl-16639489

ABSTRACT

Anti TNF-alpha drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-alpha molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.


Subject(s)
Anemia, Refractory, with Excess of Blasts/chemically induced , Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Methotrexate/adverse effects , Anemia, Refractory, with Excess of Blasts/blood , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/complications , Biopsy, Fine-Needle , Bone Marrow/pathology , Drug Therapy, Combination , Female , Humans , Infliximab , Methotrexate/administration & dosage , Methotrexate/therapeutic use , Middle Aged , Tumor Necrosis Factor-alpha/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...